

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-216)

PACANALOTAMAB

PRONUNCIATION

pa kan" a loe' ta mab

THERAPEUTIC CLAIM

Treatment of multiple myeloma

CHEMICAL NAMES

1. Immunoglobulin, anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human monoclonal bra-kan 1 single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human monoclonal bra-kan 1 single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with hexahistidine tag (Source: CAS)
2. Immunoglobulin scFv-scFv, anti-(*Homo sapiens* Tumor necrosis factor receptor superfamily member 17 (B-cell maturation protein, CD269 antigen)) *TNR17* and anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilon chain, CD3e antigen)) *CD3E*; monoclonal antibody single chain; bispecific; Variable chains anti-*TNR17* (1-243): [*Homo sapiens* VH (IGHV1-46*01 (86%) –(IGHD)-IGHJ4*01 (93%)] [8.8.14] (1-121) -tris(tetraglycylseryl) linker (122-136), [*Homo sapiens* V-KAPPA (IGKV1-33*01 (92%) –IGKJ1*01)] [6.3.9] (137-243), -seryltetraglycylseryl linker (244-249); anti-*CD3E* (250-498): [VH (*Mus musculus* IGHV10-1*02 (92%)–(IGHD)-IGHJ3*01 (87%)/*Homo sapiens* IGHV3-73*01 (87%) –(IGHD)-IGHJ5*01)] [8.10.16] (250-374) -tris(tetraglycylseryl) linker (375-389) V-LAMBDA (*Homo sapiens* IGLV7-43*01 (85%) IGLJ3*02) [9.3.9] (390-498) –pentahistidylhistidine (499-504), non-glycosylated, produced in CHO cells (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA


Sequence

QVQLVQSGAE	VKPKGASVKV	SCKASGYTFT	NHIIHWVRQA	PGQGLEWMGY	50
INPYPGYHAY	NEKFKQGRATM	TSDTSTSTVY	MELSSLRSED	TAVYYCARDG	100
YYRDTDVLDY	WGQGLTIVTS	SGGGSGGGG	SGGGSDIQM	TQSPSSLSAS	150
VGDRVITTCQ	ASQDISNYLN	WYQQKPGKAP	KLIIYYTSRL	HTGVPSRFSG	200
SGSGTDFTF	ISSLEPEDIA	TYQCQGNL	PWTFGQGTKV	EIKSGGGGSE	250
VQLVESGGGL	VQPGGSLKLS	CAASGFTFNK	YAMNWRQAP	GKGLEWVARI	300
RSKYNNYATY	YADSVKDRFT	ISRDDSKNTA	YLQMNNLKTE	DTAVYYCVRH	350
GNFGNSYISY	WAYWGQGLTV	TVSSGGGGSG	GGSGGGGSQ	TVVTQEPSTL	400
VSPGGTIVLT	CGSSTGAVTS	GNYPNWWQK	PGQAPRGLIG	GTKFLAPGTP	450
ARFSGSLLGG	KAALTLSGVQ	PEDEAEYYCV	LWYSNRWVFG	GGTKLTVLHH	500
HHHH					504

Disulfide bridges location

22-96 159-224 271-347 411-479

Modified residues



Glycosylation sites (N)

none

MOLECULAR FORMULA	C ₂₃₇₃ H ₃₅₈₄ N ₆₅₄ O ₇₄₇ S ₁₄
MOLECULAR WEIGHT	53.67 kDa
TRADEMARK	None as yet
SPONSOR	Amgen Inc.
CODE DESIGNATIONS	AMG-420
<u>CAS</u> REGISTRY NUMBER	2251756-52-0
UNII	102VUR9WQE
WHO NUMBER	11289

gbk